BK

Babaljit Kaur

Active Director Director DIN 03622153
DIN 03622153 First appointment Sep 2011 Primary industry Healthcare
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Sep 2011
Shareholding value •••• Premium profile

About Babaljit Kaur

Data last updated:

Babaljit Kaur is a Director at Rxedia Meditech Private Limited (since 2011). The company operates in Healthcare. Rxedia Meditech Private Limited reported revenue of ₹21,466 (FY 2024).

DIN 03622153
Primary Designation Director
Industry Healthcare
First Appointment 27 Sep 2011
Oldest Company Age 15 yrs
Largest company Rxedia Meditech Private Limited · ₹21,466 (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Rxedia Meditech Private Limited U72300MH2011PTC222452
Director27 Sep 20112011₹21,466 (FY 2024)Active

Board colleagues of Babaljit Kaur

Directorship timeline

Open interactive timeline →
Rxedia Meditech Private Limited
Premium access

Shareholding and investment profile for Babaljit Kaur

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Babaljit Kaur

Babaljit Kaur currently holds 1 directorship: Rxedia Meditech Private Limited (Director, since 27 Sep 2011, revenue ₹21,466 (FY 2024)).

Babaljit Kaur was first appointed on 27 Sep 2011 as Director at Rxedia Meditech Private Limited.

The current boards of Babaljit Kaur's companies include Amritpal Chitwarn Singh (Rxedia Meditech Private Limited), Sarbpal Chitwarn Singh (Rxedia Meditech Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available